<DOC>
	<DOC>NCT00305552</DOC>
	<brief_summary>Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph nodes and the skin. Skin lesions may be disfiguring and impair the quality of life. Thalidomide is a multi-target drug that has been shown to be of benefit in skin sarcoidosis in case reports. The objective is to assess the efficacy and tolerance of thalidomide in skin sarcoidosis.</brief_summary>
	<brief_title>SARCOTHAL. Thalidomide in Skin Sarcoidosis</brief_title>
	<detailed_description>The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin lesions, are eligible. They are randomized and receive either thalidomide or placebo for 3 months. Then they are given Thalidomide for a 3-month open-label period.</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Biopsy proven skin sarcoidosis Assessable target skin lesions Rapidly evolving sarcoidosis Patients necessitating a corticosteroid regimen of more than 15mg per day. Women not willing to undertake a contraceptive method. Neurologic impairment Past treatment with Thalidomide Renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Randomized controlled trial</keyword>
	<keyword>Thalidomide vs placebo</keyword>
	<keyword>skin sarcoidosis</keyword>
	<keyword>Thalidomide</keyword>
</DOC>